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Abstract
BACKGROUND—Bacillus anthracis, the causative agent of anthrax, is a potential bioterrorism 
agent. Anthrax meningitis may be a manifestation of B. anthracis infection, has high mortality, and 
requires more aggressive treatment than anthrax without meningitis. Rapid identification and 
treatment of anthrax meningitis are essential for successful management of an anthrax mass 
casualty incident.
METHODS—Three hundred six published reports from 1880 through 2013 met pre-defined 
inclusion criteria. We calculated descriptive statistics for abstracted cases and conducted 
multivariable regression on separate derivation and validation cohorts to identify clinical 
diagnostic and prognostic factors for anthrax meningitis.
RESULTS—One hundred thirty-two of 363 (36%) cases with systemic anthrax met anthrax 
meningitis criteria. Severe headache, altered mental status, meningeal signs, and other 
neurological signs at presentation independently predicted meningitis in the derivation cohort and 
are proposed as a four-item screening tool for use during mass casualty incidents. Presence of any 
one factor on admission had a sensitivity for finding anthrax meningitis of 89% (83%) in the adult 
(pediatric) validation cohorts. Anthrax meningitis was unlikely in the absence of any of these signs 
or symptoms ([LR−]=0.12 [0.19] for adult [pediatric] cohorts), while presence of two or more 
factors made meningitis very likely ([LR+]=26.5 [29.2]). Survival of anthrax meningitis was 
predicted by treatment with a bactericidal agent (P=0.005) and use of multiple antimicrobials 
(P=0.012).
CONCLUSIONS—We developed an evidence-based triage tool for screening patients for 
meningitis during an anthrax mass casualty incident; its use could improve both patient outcomes 
and resource allocation in such an event.
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Introduction
Bacillus anthracis, the bacterium that causes anthrax, is a significant public health concern 
due to its high mortality rate, near global ubiquity, and prior use as a biological weapon. 
Although modern critical care has improved outcomes, the mortality rate of inhalation 
anthrax remains high – ~90% pre-2001 [1]and 43% since 2001 [2–6]. Anthrax meningitis, a 
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common complication of anthrax, has a 94% reported fatality rate [7]. Well known as a 
complication of primary inhalation anthrax, [1]meningitis may also complicate primary 
anthrax infections of the gastrointestinal tract, [8] skin, [7] and soft tissue [9] and it may 
occurr in patients with systemic anthrax with no recognized port of entry [10]. Newly 
revised anthrax treatment guidelines dictate more aggressive treatment protocols for patients 
with meningitis than for those without [11].
Radiographic and laboratory capacity may be insufficient to treat patients according to 
conventional standards in an anthrax mass causality incident. Crisis standards of care – 
intended to provide the greatest good to the greatest number in the shortest time – would 
likely be implemented; and patient triage would most likely be based on readily available 
data [12, 13]. Once healthcare personnel have triaged patients into suspected anthrax and 
non-anthrax groups, those with presumed anthrax will still need to be sorted into meningitis 
and non-meningitis subsets. Prior studies have proposed diagnostic criteria to differentiate 
inhalation anthrax from influenza-like illness [14] and community-acquired pneumonia [15]. 
However, previous reviews of anthrax meningitis have not proposed diagnostic criteria that 
could be used by clinicians during a mass casualty incident, in which diagnostic testing and 
antimicrobial availability may be severely limited. Therefore, we performed a systematic 
review of English-language published cases of systemic anthrax from 1880 through 2013 to 
identify the clinical presentation, patient factors, treatment, and outcomes of patients who 
developed anthrax meningitis. Our objectives were to: 1) improve the ability of clinicians to 
efficiently triage and monitor systemically ill patients for meningitis during an anthrax mass 
casualty incident, 2) identify patient and therapeutic factors associated with anthrax 
meningitis outcomes, and 3) inform public health policy regarding preparedness for and 
response to an anthrax mass casualty incident.
Guiding Questions for Literature Review
We asked what signs or symptoms could predict meningitis in patients with systemic 
anthrax, compared to definitive diagnostic tests such as lumbar puncture and culture. We 
also asked what clinical variables and therapies were associated with survival. We chose to 
use systemic (Appendix 1. Definitions, Systemic) rather than inhalation anthrax as our 
denominator because meningitis can complicate any type of anthrax [7] and notable 
inhalation anthrax outbreaks [2, 16] include cases of noninhalation anthrax.
Methods
Our case definitions are listed in Appendix 1.
Data Sources and Search String
We utilized systematic methods to identify published descriptions of cases with systemic 
anthrax. A search strategy was developed by anthrax subject matter experts (SMEs) and 
librarians at the Centers for Disease Control and Prevention (CDC) and Cornell Weill 
Medical College. Twelve databases were searched from inception through October 2013: 
Commonwealth Agricultural Bureau (1973 –), Cumulative Index to Nursing and Allied 
Health Literature (1981–), Defense Technical Information Center (1950 –), EconLit (1886 
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–), Embase (1988 –), Federal Research in Progress (1930 –), Global Health (1910 –), 
Medline (1946 –), National Technical Information Service (1964 –), Web of Science (1980 
–), WorldCat (1967 –), and World Health Organization Library Database (1948 –).
Our search string terms captured English-language anthrax literature related to general triage 
of patients in an anthrax mass casualty incident, diagnostic testing for meningitis, and 
diagnostic test characteristics (Appendix 2: triage and meningitis search string syntax). A 
manual search of the bibliographies of review articles and SME-identified articles/
government reports identified additional full-text articles/reports for review.
Study Selection
Following de-duplication, 4622 articles were excluded through title and abstract review 
because they appeared to lack a case report, case series, or line list describing any patients 
with anthrax (Appendix Figure 1: Flow Diagram of Study Selection Strategy). Following 
full text review, 515 of the remaining 821 articles were excluded because they lacked clinical 
information about individual patients with confirmed cases of anthrax whose reports 
included vital signs, white blood cell counts, or mention of death.
Data Extraction and Cleaning
We abstracted the following data: author; title; demographic information; chief complaint; 
presence and timing of symptoms, signs, and laboratory and imaging findings; key 
laboratory results over the course of treatment; key complications and their timing; 
treatment(s); and outcomes including autopsy findings. Extraction of selected articles was 
completed independently and in duplicate; discrepancies were resolved through discussion 
of the original publication and by a third party arbiter as needed. Compiled case data were 
corrected for cases described in multiple publications.
Case Definitions and Completeness/Quality Assessment
Appendix 1 defines anthrax, systemic illness, meningitis, fulminant and prodromal status, 
geographic region, and publication type. We assessed case report completeness and quality 
by a 15-item checklist that was adapted from the CAse REport (CARE) checklist [17] and 
the toxicology case report checklist of Lavergne et al [18] and included demographic, 
medical, treatment, and outcome data (Appendix 1). If a case report contained extractable 
information for a given item it was scored 1; otherwise, 0.
Data Synthesis and Analysis
We report overall descriptive statistics including patient characteristics, primary route of 
transmission (if known), duration of illness prior to start of countermeasures (e.g., 
antimicrobials), symptoms and signs at presentation, initial laboratory results, treatment 
course, presence of meningitis, outcomes, and completeness score for patients of any age 
with systemic anthrax. Temporal and geographic trends are presented as supporting 
information. Since a number of authors [19–21] have suggested that the clinical presentation 
and prognosis of children may differ from those of adults, we stratified our results by age 
(0–17 years old, 18–50, >50).
Katharios-Lanwermeyer et al. Page 4













We randomly divided adult cases with systemic anthrax into separate derivation (80%, 
n=246) and validation (20%, n=61) cohorts. Comparisons of sex, age, meningitis status, type 
of care, and time period showed the cohorts were comparable (data not shown). “Suspect” 
meningitis cases were excluded from the derivation (n=7) and validation cohorts (n=1) to 
improve the specificity of our findings. All pediatric cases (n=56) were included in a second 
validation cohort.
We used multivariable logistic regression to determine independent predictors of anthrax 
meningitis in the derivation cohort and tested differing combinations of predictors as a 
potential anthrax meningitis screening tool. We chose variables for this tool based on a 
combination of statistical significance on univariate analysis, accessibility (i.e., subjective 
and objective assessments that could be rapidly performed in the setting of a mass casualty 
incident), and historical clinical practice (e.g., elicitation of “meningeal signs”). Variables 
considered included age, sex, severe (e.g., “severe,” “throbbing,” and “worsening”) 
headache, altered mental status, meningeal signs (i.e., Kernig sign, Brudzinski sign, jolt 
accentuation test, nuchal rigidity, photophobia, and meningismus), other neurological signs 
(nonheadache, nonmeningeal signs including seizure, cranial nerve signs, limb weakness, 
and papilledema), fever/chills, and nausea/vomiting.
We selected the two best models based on calculated sensitivity, specificity, and positive and 
negative likelihood ratios (LR+, LR−) in the derivation cohort [22, 23]. These were then 
evaluated using data from the adult and pediatric validation cohorts. To assess possible 
reporting bias, a sensitivity analysis was conducted by applying the two models to cases 
with completeness scores in the top 50% and 75%.
Absence of reported data on symptoms, signs, laboratory results, and treatments was treated 
in the same manner as a negative response. We excluded cases with missing data from 
quantitative statistics as denoted in Tables 1 and 2. Symptoms and signs were considered to 
be “on presentation” if they occurred on or before the first day of hospitalization or autopsy 
or if the article mentioned a symptom or sign without specifying a timeframe. We 
considered a two-tailed p-value of <0.05 to be statistically significant and performed 
analyses using SAS software, version 9.3 (SAS Institute Inc., Cary, North Carolina).
Findings
We identified 6,054 potentially relevant publications from our search and 1056 additional 
articles from SMEs and a manual search of review bibliographies. This strategy yielded 225 
reports describing 363 systemic anthrax cases (Appendix Figure 1 and Appendix 3). Most 
were adult (84.6%), male (79.5%), and hospitalized (93.4%); 36.9% survived. A few (1.9%) 
received outpatient care and 3.0% died before presentation. Of the 132 (36.4%) with 
meningitis, 88.6% were confirmed; 5.3%, probable; and 6.1%, suspected. The primary 
routes of transmission for patients with systemic illness were: 51.8%, cutaneous; 22.9%, 
inhalation; 13.0%, ingestion; and 2.2%, injection. Thirty-two (8.8%) had no identifiable 
route of transmission. Date and location of report and temporal trends in treatment are 
described by Appendix Figures 2, 3, and 4. Case report quality on our 15-point scale ranged 
from five to 15, with a median score of 11 and 95% of reports scoring eight or higher.
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Clinical Presentation and Diagnosis
Clinical signs and symptoms of all adults (≥18 years) and children (0 to 17 years) presenting 
with systemic anthrax are described in Tables 1A and 1B. We found no significant age or sex 
differences among adults with systemic anthrax with and without meningitis (Table 1A). 
Symptoms associated with ~ 3-fold increased risk of meningitis in univariate analysis 
included fever/chills, nausea/vomiting, and headache. Severe headache was uncommon, but 
was associated with a higher risk of meningitis. A number of neurological signs were much 
more common (>20-fold) in meningitis cases, including altered mental status, loss of 
consciousness, meningeal signs, and other neurological deficits (P<0.001 for each 
comparison). Adults with meningitis had higher respiratory rates than those without.
Six- to 12-year-olds were at increased risk of developing meningitis compared to 0- to 1-
year-olds (p=0.0207) (Table 1B). While multiple signs and symptoms were strongly 
associated with meningitis in children (including nausea/emesis, severe headache, altered 
mental status, loss of consciousness, meningeal signs, and other neurologic deficits), age-
defined tachypnea was present in most (95.0%) systemically ill children and showed no 
significant association with meningitis.
Cerebrospinal Fluid (CSF) Results in Anthrax Meningitis
The CSF was described as hemorrhagic in two-thirds of the 65 cases with meningitis who 
lacked evidence of subarachnoid hemorrhage (SAH) (by either imaging or autopsy) and 
underwent a lumbar puncture. Among those without SAH or frankly hemorrhagic CSF, the 
mean white blood cell (WBC) (n=13) and red blood cell (RBC) (n=7) counts were 3.4 × 
109/L and 9.2 × 109/L and the mean protein (n=11) and glucose (n=11) levels were 7.3 g/L 
and 2.1 mmol/L, respectively.
Prognostic Indicators
Adults were more likely than children to die from systemic anthrax (P=0.002). The presence 
of meningitis increased mortality for systemic anthrax in both adults (Table 1A) and children 
(Table 1B). Adults and children with systemic anthrax with and without meningitis had 
similar durations of illness prior to onset of treatment (data not shown).
Mortality among cases who had meningitis was associated with multiple factors (Table 2). 
Compared to survivors, persons who died with meningitis were likelier to present with 
diminished mental status and higher peripheral white counts and CSF leukocytes; almost 
half of fatalities and one-tenth of survivors had hemorrhagic CSF (P=0.051). Cases aged 18–
50 years appeared to be at increased risk of death compared to younger and older age-
groups; although they accounted for a majority of the cases (61% versus 15% for younger 
and 24% for older), only one of ten survivors was in this age-group. Cases aged <18 years 
were more likely than those aged 18–50 to have a route of exposure other than inhalation or 
unknown (P=0.012) and to have received multiple antimicrobials (P=0.022). Cases >50 
years old were more likely than those aged 18–50 to have cutaneous illness (P=0·036) and to 
have received a bactericidal antimicrobial (P<0·001) and steroids (P=0·018). On average, the 
younger and older age-groups were reported more recently (year 1972 and 1980, 
respectively) than the 18- to 50-year age-group (1960). After multivariable logistic analysis 
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that adjusted for year (<1960 vs >1960), infection route (inhalation/unknown vs other), and 
treatment (bactericidal antimicrobials, multiple antimicrobials, or steroids vs other), children 
were still less likely to die than adults aged 18–50 (OR 0.06, 95% Confidence Interval (CI) 
0.00–0.70), but both groups of adults had similar risk of death.
Survival among all anthrax meningitis cases was associated with presence of headache 
(P=0.039) and with nausea or vomiting (P=0.055) on admission. However, when the analysis 
was limited to either the 21 alert patients or the 56 non-comatose patients, these variables no 
longer predicted survivorship (P> 0.10 for each). All ten meningitis survivors received a 
bactericidal antimicrobial; seven survivors received multiple antimicrobials. Neither receipt 
of antitoxin/antiserum nor administration of systemic corticosteroids was associated with 
improved survival.
Variables associated with early (pre-hospital or first day of hospitalization) mortality 
included male sex, presentation with fever and/or chills, unconsciousness on presentation, 
and higher CSF RBCs.
Anthrax Meningitis Diagnostic Models
No single sign or symptom reliably identified anthrax meningitis in patients with systemic 
anthrax; for example, headache had a sensitivity of 35% and specificity of 82% in the 
derivation cohort (Table 3). In our derivation cohort, a four-item screening tool (severe 
headache, altered mental status, meningeal signs, and other neurological signs) that 
presumptively identified anthrax meningitis with either one (Model 4) or two (Model 5) 
positive responses, had better combined performance than three- or five-item screening 
tools. A negative response to all 4 questions (Model 4) had the lowest LR− (0.12) of the 
tested models in the derivation cohort; conversely, two or more positive responses to the 
same screening questions (Model 5) yielded a very high LR+ (26.5).
In the adult and pediatric validation cohorts, a single positive response (Model 4) had an LR
+ of 6.26 and 7.71 and sensitivity of 89% and 83%, respectively. (See Table 4 for complete 
test characteristics.)
Sixteen (12%) cases known to have anthrax meningitis were not identified as such by our 
screening tool in either the derivation or validations cohorts (i.e. false negatives). However 
seven (44%) of these would have been identified after initial presentation had the screening 
tool been used for “monitoring” after day one.
Although reports on adults with meningitis did have more complete descriptions than those 
without (mean completeness score 11.3 [SD=2.0] vs 10.5 [2.1], P<0.001), restricting the 
analysis to cases with scores >11 (top 50%) or >9 (top 75%) had minimal impact on 
calculated test characteristics.
Interpretation
We found that a 4-item screening tool – assessing severe headache, altered mental status, 
meningeal signs, and other neurological signs – has good discriminatory power for two key 
tasks: (1) identifying patients with systemic anthrax who are likely to have anthrax 
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meningitis and therefore should be started on specific therapies (e.g., triple antibiotic 
coverage including a bactericidal agent[11]) and (2) identifying patients with systemic 
anthrax who are unlikely to have anthrax meningitis and therefore do not require anthrax 
meningitis-specific countermeasures. Hence, patients with two or more positive responses 
may be categorized as presumptive anthrax meningitis, while patients with no positive 
responses may be categorized as non-meningitis systemic anthrax. Patients with only one 
positive response fall in the middle; in a crisis setting with overwhelming casualties, they 
may be managed by initiation of presumptive anti-anthrax meningitis treatment[24–27]. In a 
contingency setting, these patients may be prioritized for lumbar puncture and/or 
neuroimaging to individualize their treatment plans.
Four of our findings have important policy implications. First, our data, from the largest case 
series of systemic anthrax yet assembled, confirms that approximately one third of these 
cases are complicated by meningitis, and that these patients face double the mortality risk of 
non-meningitis cases (92.4% vs. 46.0%). Effective public health response to the intentional 
aerosol release of B. anthracis spores should, therefore, include rapid screening to identify 
those with anthrax meningitis to facilitate effective patient and resource management.
Second, both adults and children with anthrax meningitis either present with or develop a 
small number of signs and symptoms that can reliably distinguish them from patients with 
non-meningitic systemic anthrax. Our simple screening tool has excellent test 
characteristics, which we believe will be of use to public health agencies worldwide.
Third, we confirm increased survival of patients with meningitis who received bactericidal 
antimicrobials and/or multiple antimicrobials. Treatment of anthrax meningitis is hampered 
by the poor blood-brain barrier penetration of antitoxins [28, 29] and various antimicrobials. 
There may be a future role for neuroprotective agents in the management of anthrax 
meningitis, as some are beginning to show promise for the treatment of intracranial 
hemorrhage [30–32].
Fourth, we found that almost half of systemic anthrax patients who eventually developed 
meningitis (7 of 16) lacked suggestive signs or symptoms on presentation, underscoring the 
need for mandatory periodic reassessment of these patients.
Fatal anthrax meningitis cases in this series share a number of characteristics with patients 
who die from non-anthrax bacterial meningitis and SAH; these include presenting with 
altered mental status, increased peripheral and/or cerebrospinal fluid white count, and 
hemorrhagic CSF [33–35]. Due to the small number of reported observations, we could not 
assess the relation to outcome of comorbidities, arrhythmias, hypotension, hyponatremia, 
decreased platelets, or decreased hematocrit – known risk factors for poor outcome in non-
anthrax meningitis and SAH [33–40].
Limitations
Publication bias (that is, preferential publication of the most dramatic or successfully treated 
cases) may have led us to conclusions that are not in fact representative of all anthrax 
meningitis cases. Data were extracted and assessed from English-language retrospective case 
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reports and our conclusions rely on publications of varying origin, detail, and quality. 
Underlying medical comorbidity or pertinent negative clinical signs and symptoms may not 
have been reported in these cases. Finally, identified anthrax cases were published over a 
100-year period, during which treatment options and supportive care techniques advanced 
greatly. Thus it is difficult to comment on the effectiveness of newer treatment modalities 
and guidelines.
Conclusions
We developed a simple four-item screening tool that accurately identifies systemic anthrax 
cases that are complicated by meningitis on the basis of clinical symptoms and signs alone. 
Efficient identification of these patients during an anthrax mass casualty incident may result 
in improved patient outcomes and more effective use of scarce resources. Our findings 
should be of interest and assistance to emergency response professionals and public health 
agencies worldwide.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix 1. Definitions
Anthrax cases were confirmed in patients by microscopic identification (e.g., Gram stain 
after 1886), culture, paired sera, polymerase chain reaction, enzyme-linked immunosorbent 
assay, immunohistochemistry, animal inoculation, or by epidemiological linkage with a 
confirmed case or positive “environmental (e.g., shaving brush, hide)” culture.
Systemic illness was considered to be present in 1) adults 18 years of age and older who met 
any of the following criteria: temperature <36 or >38 degrees centigrade or described as 
“hypothermic,” pulse >90 per minute or described as “tachycardic,” respiratory rate >20 per 
minute or described as “tachypneic,” systolic blood pressure <90mm Hg or described as 
“hypotensive” or “in shock,” mean arterial pressure (MAP) <70mm Hg, or white blood cell 
count >12,000 cells/μL or <4,000 cells/μL; 2) children under 18 years of age who met any of 
the age-specific sepsis criteria described by Goldstein; and 3) any aged patient with a) any 
secondary organ involvement (e.g., gastrointestinal, pulmonary complications), b) evidence 
of B. anthracis from a normally sterile site (e.g., blood or CSF), c) evidence of ascites or 
pleural fluid, or d) death.
Anthrax meningitis was analyzed as a dichotomous variable but had confirmed, probable, 
and suspect subcategories dependent on the following criteria: Confirmed anthrax meningitis 
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was defined as culture of B. anthracis from either the CSF or brain; microscopic evidence 
(e.g., Gram stain) from either the CSF or brain; or positive culture or microscopic evidence 
from a non-intracranial source accompanied by CSF findings consistent with meningitis 
(e.g., WBCs > .005 × 109/L). Probable anthrax meningitis was defined as CSF described as 
bloody, cloudy, or xanthochromic or CT, MRI, or autopsy evidence of a subarachnoid or 
intracranial hemorrhage or encephalitis. Suspect anthrax meningitis was defined as the 
presence of meningeal signs (i.e., Kernig sign, Brudzinski sign, nuchal rigidity, photophobia, 
meningismus) or nonheadache, nonmeningeal neurological signs (e.g., seizure, cranial nerve 
signs, limb weakness, papilledema).
Fulminant disease was considered to be present in patients who were described as being 
cyanotic or in shock; who, in the modern era, needed mechanical ventilation or vasopressors; 
or who died prior to or the day of arrival. Those who lacked these features were considered 
to have prodromal disease.
Country codes and geographic regions were assigned according to UN criteria.
To measure case report completeness and quality, we developed a previously described (See 
Case Definitions and Completeness/Quality Assessment) checklist from two sources. Our 
checklist comprised 15 items: age, sex, occupation or exposure, underlying medical 
condition, chief complaint, clinical findings, laboratory or imaging findings, timing of 
course of illness, treatments or interventions, countermeasure-specific treatment, timing of 
any treatments, fatal/nonfatal outcome, ICU admission, length of stay, morbidity description 
(or autopsy information).
Appendix 2. Triage and Meningitis Search String Syntax
Triage OR (acute ADJ care) OR EMS OR (emergenc* ADJ (medic* OR room* OR 
department*)) OR ER OR diagnos?s OR diagnostic* OR (symptom ADJ (assessment* OR 
evaluation*)) OR (prodromal ADJ2 (symptom* OR state* OR stage* OR sign* OR phase*)) 
OR (urgent ADJ care) OR (needs ADJ assessment*) OR symptom* OR (healthcare ADJ 
need*) OR (critical ADJ care) OR (constellation ADJ2 (sign* OR symptom*)) OR ((rapid 
OR quick) ADJ2 test*) OR (rapid ADJ assessment*) OR ((patient OR clinical) ADJ 
(assessment* OR evaluation*)) OR (disaster ADJ medicine) OR ICU OR (intensive ADJ 
care) OR (surge ADJ (capacity OR medical)) OR ((mass OR (large ADJ scale)) ADJ 
screening) OR (healthcare ADJ2 facilit*) OR (medical ADJ plan*) OR (medical ADJ 
priorit*) OR ((high ADJ risk) ADJ (screening OR patient*)) OR ((low ADJ risk) ADJ 
patient*) OR ((multiphasic OR medic*) ADJ screening) OR presentation* OR (decision 
ADJ making) OR prodom* OR fulmin* OR (gram ADJ stain) OR outpatient* OR 
discharge* OR hospitaliz* OR score OR sign OR toxemia OR effusion OR ascites OR shock 
OR h?emorrhag* OR CSF OR ( sensitivity ADJ specificity)
AND
Anthrax OR (Bacillus Anthracis) OR (B Anthracis) OR Charbon OR Charbonneuse OR 
Milzbrand OR Antraks OR Antrax OR Carbunclo OR Carbunco OR (woolsorter* OR (wool 
ADJ sorter)) OR ragpicker*
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Systematic literature review includes 363 systemic anthrax cases; a third with meningitis. 
Presence of severe headache, meningeal signs, altered mental status, or other 
neurological symptoms on admission predicted anthrax meningitis. A screening tool is 
described based on these four items.
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Flow Diagram of Study Selection Strategy
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